{"id":"dimepheptanol","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Opioid","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Narcotics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"methadol","offLabel":[],"synonyms":["dimepheptanol","bimethadol","methadol","racemethadol"],"timeline":[],"approvals":[],"brandName":"Methadol","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Methadol is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock to open the cell or block other keys from entering. However, the specific lock that Methadol fits into and how it affects the cell's behavior are still unknown.","oneSentence":"Methadol is thought to work by interacting with a specific molecular target, although its exact mechanism of action is currently unknown.","technicalDetail":"Methadol's mechanism of action is believed to involve interaction with a specific molecular target, although the exact nature of this interaction is currently unclear. Further research is needed to determine the compound's pharmacological properties and potential therapeutic applications."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3730","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DIMEPHEPTANOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIMEPHEPTANOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:38:47.642343","biosimilars":[],"competitors":[],"genericName":"dimepheptanol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01935830","phase":"EARLY_PHASE1","title":"LAAM-HAART PET Imaging","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-08","conditions":["Healthy Volunteers"],"enrollment":10,"completionDate":"2015-09"},{"nctId":"NCT00000300","phase":"PHASE4","title":"Feasibility Study of Take-Home LAAM Medication - 3","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"1995-03","conditions":["Opioid-Related Disorders"],"enrollment":0,"completionDate":""},{"nctId":"NCT00158288","phase":"PHASE2","title":"The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1997-03","conditions":["Behavior Therapy","Cocaine","Contingency Management","Heroin Dependence","LAAM","Opioid Dependence","Substance-Related Disorders","Alcohol & Drug Use"],"enrollment":140,"completionDate":"2001-08"},{"nctId":"NCT00000356","phase":"PHASE2","title":"Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1991-06","conditions":["Opioid-Related Disorders","Substance-Related Disorders"],"enrollment":0,"completionDate":"1992-10"},{"nctId":"NCT00218127","phase":"PHASE2","title":"Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-11","conditions":["Heroin Dependence","Opioid-Related Disorders"],"enrollment":142,"completionDate":"2005-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"NNB4I01PA7","CHEBI":"CHEBI:135332","INN_ID":"613","UMLSCUI":"C0729033","ChEMBL_ID":"CHEMBL368591","PUBCHEM_CID":"28397","MESH_DESCRIPTOR_UI":"D008692"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methadol, also known as Dimepheptanol, is a small molecule compound with unknown target and drug class. Its commercial status and approved indications are unclear. As a research compound, it may have potential therapeutic applications, but further investigation is needed to determine its efficacy and safety. Key safety considerations are unknown, and its half-life, bioavailability, and generic manufacturers are also unclear. Further research is required to fully understand Methadol's properties and potential uses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}